Jazz’s move into the KRAS category comes shortly after AstraZeneca licensed a KRAS G12D inhibitor from Chinese biotech Usynova for $24 million upfront in a deal that also includes up to $395 ...
1月15日，中国国家药监局药品审评中心(CDE)官网最新公示，阿斯利康(AZN.US)1类新药AZD0022获得临床试验默示许可，拟开发治疗携带KRAS G12D突变的晚期 ...
KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback